PDS Biotech launches VERSATILE-003 Phase 3 trial to evaluate Versamune® HPV with pembrolizumab for treating HPV16-positive head and neck cancer. PDS Biotechnology Corporation has announced the launch ...
Early findings of two studies shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. Early findings of two studies from the University of Michigan Rogel Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results